Clinical trial
Phase4, to Compare Efficacy and Safety of Therapeutic Vaccination With Intensified Schedule Plus Pegylated Interferon Dual Therapy on Seroclearance of HBS Antigen in Patients With Complete Virological Response Induced by Entecavir
NCT02097004 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase4, to Compare Efficacy and Safety of Therapeutic Vaccination With Intensified Schedule Plus Pegylated Interferon Dual Therapy on Seroclearance of HBS Antigen in Patients With Complete Virological Response Induced by Entecavir
- Lead sponsor
- Seoul National University Hospital
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 30, 2014
- Completion date
- March 13, 2018
- Enrollment
- 111 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.